Insmed

Artisan Global Opportunities said Insmed was its biggest detractor in Q2 after trimming the position, citing Q1 sales modestly below elevated expectations due to concerns around discontinuation, therapy continuation and seasonality. The firm still views BRINSUPRI®'s rapid launch and uptake as encouraging and believes the therapy is on track for blockbuster-level sales and remains well tolerated. Insmed closed at $121.51 on Sept 1, returned 25.42% over the past month, is down 13.45% over 52 weeks, and has a market capitalization of $27.14 billion. » Mais em finance.yahoo.com

Japan’s Ministry of Health has approved BRINSUPRI (Brensocatib 25 mg) from Insmed for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older. The once-daily oral therapy is the first treatment approved in Japan for NCFB and complements existing approvals in the US and Europe. The decision is based on the phase-3 ASPEN study, which showed a reduction in pulmonary exacerbations and positive secondary endpoints over 52 weeks; common adverse events included COVID-19, nasopharyngitis, cough and headache. » Mais em de.investing.com

Insmed reports strong Q2 figures and a jump in sales of its lung drug Brinsupri, whose revenue rose quarter-on-quarter by 48.7% to $309.2 million. In response, management raised the revenue outlook for 2026 to as much as $1.87 billion, thereby beating consensus estimates. The stock reacted with notable price gains and increased trading volume. » Mais em finanzen.net